MX2016008429A - Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. - Google Patents
Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.Info
- Publication number
- MX2016008429A MX2016008429A MX2016008429A MX2016008429A MX2016008429A MX 2016008429 A MX2016008429 A MX 2016008429A MX 2016008429 A MX2016008429 A MX 2016008429A MX 2016008429 A MX2016008429 A MX 2016008429A MX 2016008429 A MX2016008429 A MX 2016008429A
- Authority
- MX
- Mexico
- Prior art keywords
- inflammatory disease
- metabolic syndrome
- treat
- pharmaceutical composition
- phenol
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title abstract 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title abstract 3
- 208000027866 inflammatory disease Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title 1
- 150000002989 phenols Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se proporciona un derivado de piranocromenil fenol, una sal farmacéuticamente aceptable del mismo, o un solvato del mismo. También se proporciona una composición farmacéutica para prevenir o tratar el síndrome metabólico o enfermedad inflamatoria que comprende el mismo. La presente invención es eficaz para prevenir o tratar el síndrome metabólico o la enfermedad inflamatoria y es químicamente estable.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130162909 | 2013-12-24 | ||
| KR1020140181951A KR102344479B1 (ko) | 2013-12-24 | 2014-12-17 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
| PCT/KR2014/012688 WO2015099392A1 (ko) | 2013-12-24 | 2014-12-23 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016008429A true MX2016008429A (es) | 2017-02-23 |
| MX374944B MX374944B (es) | 2025-03-06 |
Family
ID=53788040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008429A MX374944B (es) | 2013-12-24 | 2014-12-23 | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9783551B2 (es) |
| EP (1) | EP3098224B1 (es) |
| JP (2) | JP6620096B2 (es) |
| KR (1) | KR102344479B1 (es) |
| CN (1) | CN105849111B (es) |
| AU (1) | AU2014370697B2 (es) |
| BR (1) | BR112016011281B1 (es) |
| CA (1) | CA2929001C (es) |
| CY (1) | CY1121554T1 (es) |
| DK (1) | DK3098224T3 (es) |
| ES (1) | ES2718878T3 (es) |
| HR (1) | HRP20190573T1 (es) |
| HU (1) | HUE043902T2 (es) |
| IL (1) | IL245908B (es) |
| MX (1) | MX374944B (es) |
| NZ (1) | NZ720328A (es) |
| PL (1) | PL3098224T3 (es) |
| PT (1) | PT3098224T (es) |
| SG (1) | SG11201604371PA (es) |
| TW (1) | TWI585093B (es) |
| WO (1) | WO2015099392A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102344479B1 (ko) * | 2013-12-24 | 2021-12-29 | 주식회사 글라세움 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
| SG11201811796SA (en) * | 2016-06-29 | 2019-02-27 | Glaceum Inc | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same |
| CA3039326C (en) * | 2016-10-04 | 2022-09-20 | Glaceum Inc. | Method for synthesizing 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and optical isomer of thereof |
| TWI804600B (zh) * | 2018-04-03 | 2023-06-11 | 南韓商格雷森伍股份有限公司 | 3-苯基-2,8-二氫吡喃[2,3-ƒ]苯并哌喃衍生物的合成方法 |
| KR20190116099A (ko) | 2018-04-03 | 2019-10-14 | 주식회사 글라세움 | 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물 |
| KR20200105198A (ko) | 2019-02-28 | 2020-09-07 | 주식회사 글라세움 | 신경계 질환의 예방 또는 치료용 약학적 조성물 |
| KR102692932B1 (ko) | 2019-07-30 | 2024-08-07 | 주식회사 글라세움 | 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법 |
| KR20220166203A (ko) | 2021-06-08 | 2022-12-16 | 주식회사 글라세움 | 퇴행성 안질환의 예방 또는 치료용 약학적 조성물 |
| CN113616548B (zh) * | 2021-09-02 | 2023-04-28 | 河南科技大学 | 一种水溶性光甘草定包合物及其制备方法 |
| EP4509510A4 (en) * | 2022-04-12 | 2025-10-15 | Glaceum Inc | Process for the preparation of 3-PHENYL-2,3,4,9,10-HEXAHYDROPYRANO[2,3-F]CHROMENE derivatives |
| CN114903879B (zh) * | 2022-06-23 | 2023-10-31 | 东北大学 | 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 |
| KR20240113389A (ko) | 2023-01-12 | 2024-07-22 | 주식회사 글라세움 | 퇴행성 골관절염의 예방 또는 치료용 약학적 조성물 |
| KR20250081177A (ko) | 2023-11-29 | 2025-06-05 | 한국화학연구원 | Hsg4112 r형을 유효성분으로 포함하는 반려동물의 비만 예방, 개선 또는 치료용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1599602A (zh) | 2001-10-11 | 2005-03-23 | 钟渊化学工业株式会社 | 过氧化物酶体增殖剂应答性受体配体剂及其制备方法 |
| KR100565423B1 (ko) * | 2003-10-20 | 2006-03-30 | 빅 바이오 주식회사 | 이소플라반 유도체 또는 이소플라벤 유도체의 제조방법 |
| JP2006008604A (ja) * | 2004-06-25 | 2006-01-12 | Kuraray Co Ltd | イソフラバン誘導体の製造方法 |
| WO2007058480A1 (en) | 2005-11-16 | 2007-05-24 | Md Bioalpha Co., Ltd. | Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin |
| KR102344479B1 (ko) * | 2013-12-24 | 2021-12-29 | 주식회사 글라세움 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
-
2014
- 2014-12-17 KR KR1020140181951A patent/KR102344479B1/ko active Active
- 2014-12-23 MX MX2016008429A patent/MX374944B/es active IP Right Grant
- 2014-12-23 SG SG11201604371PA patent/SG11201604371PA/en unknown
- 2014-12-23 HR HRP20190573TT patent/HRP20190573T1/hr unknown
- 2014-12-23 BR BR112016011281-4A patent/BR112016011281B1/pt active IP Right Grant
- 2014-12-23 CN CN201480070935.5A patent/CN105849111B/zh active Active
- 2014-12-23 US US15/037,230 patent/US9783551B2/en active Active
- 2014-12-23 EP EP14873860.2A patent/EP3098224B1/en active Active
- 2014-12-23 NZ NZ720328A patent/NZ720328A/en unknown
- 2014-12-23 HU HUE14873860 patent/HUE043902T2/hu unknown
- 2014-12-23 AU AU2014370697A patent/AU2014370697B2/en active Active
- 2014-12-23 DK DK14873860.2T patent/DK3098224T3/da active
- 2014-12-23 WO PCT/KR2014/012688 patent/WO2015099392A1/ko not_active Ceased
- 2014-12-23 JP JP2016540481A patent/JP6620096B2/ja active Active
- 2014-12-23 ES ES14873860T patent/ES2718878T3/es active Active
- 2014-12-23 CA CA2929001A patent/CA2929001C/en active Active
- 2014-12-23 PT PT14873860T patent/PT3098224T/pt unknown
- 2014-12-23 PL PL14873860T patent/PL3098224T3/pl unknown
- 2014-12-24 TW TW103145316A patent/TWI585093B/zh active
-
2016
- 2016-05-29 IL IL245908A patent/IL245908B/en active IP Right Grant
-
2018
- 2018-03-23 JP JP2018056783A patent/JP2018135343A/ja active Pending
-
2019
- 2019-04-16 CY CY20191100423T patent/CY1121554T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL245908A0 (en) | 2016-08-02 |
| EP3098224B1 (en) | 2019-01-30 |
| WO2015099392A1 (ko) | 2015-07-02 |
| CY1121554T1 (el) | 2020-05-29 |
| EP3098224A4 (en) | 2017-07-05 |
| MX374944B (es) | 2025-03-06 |
| CN105849111A (zh) | 2016-08-10 |
| US9783551B2 (en) | 2017-10-10 |
| PT3098224T (pt) | 2019-04-26 |
| HRP20190573T1 (hr) | 2019-05-17 |
| NZ720328A (en) | 2018-02-23 |
| KR20150075030A (ko) | 2015-07-02 |
| CN105849111B (zh) | 2018-05-04 |
| PL3098224T3 (pl) | 2019-07-31 |
| SG11201604371PA (en) | 2016-07-28 |
| EP3098224A1 (en) | 2016-11-30 |
| CA2929001A1 (en) | 2015-07-02 |
| JP2018135343A (ja) | 2018-08-30 |
| TW201607949A (zh) | 2016-03-01 |
| JP2017501163A (ja) | 2017-01-12 |
| AU2014370697A1 (en) | 2016-06-16 |
| ES2718878T3 (es) | 2019-07-05 |
| HUE043902T2 (hu) | 2019-10-28 |
| BR112016011281A2 (es) | 2017-08-08 |
| BR112016011281B1 (pt) | 2021-11-16 |
| US20160272650A1 (en) | 2016-09-22 |
| CA2929001C (en) | 2018-02-20 |
| JP6620096B2 (ja) | 2019-12-11 |
| KR102344479B1 (ko) | 2021-12-29 |
| IL245908B (en) | 2020-08-31 |
| DK3098224T3 (da) | 2019-05-13 |
| TWI585093B (zh) | 2017-06-01 |
| AU2014370697B2 (en) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
| ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
| BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| CL2015003460A1 (es) | Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica | |
| CL2015003679A1 (es) | Agentes terapéuticos para el uso en la profilaxis y/o el tratamiento de trastornos del movimiento hiperquineticoico | |
| AR106415A1 (es) | Composición farmacéutica para el tratamiento del dolor | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| ES2721922T3 (es) | Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
| MX2017008879A (es) | Composicion farmaceutica para el tratamiento de la micosis. | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| CL2016000542A1 (es) | Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: GLACEUM, INC. |
|
| FG | Grant or registration |